| Literature DB >> 25844060 |
Stephanie Klinzing1, Giovanna Brandi1, Paul A Stehberger1, Dimitri A Raptis2, Markus Béchir1.
Abstract
BACKGROUND: Early prediction of outcome would be useful for an optimal intensive care management of liver transplant recipients. Indocyanine green clearance can be measured non-invasively by pulse spectrophometry and is closely related to liver function.Entities:
Keywords: Hospital mortality; Indocyanine green liver testing; Length of stay in the ICU; MELD score
Mesh:
Substances:
Year: 2014 PMID: 25844060 PMCID: PMC4384315 DOI: 10.1186/1471-2253-14-103
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.217
Demographic data of the recipients and donors (n = 50)
| Recipient | Donor | |
|---|---|---|
| Male (%) | 37 (74%) | 36 (72%) |
| Female (%) | 13 (26%) | 14 (28%) |
| Age (yrs) | 51.3 ± 11.1 (16 - 67) | 53.2 ± 17.2 (19 - 86) |
| BMI (kg/m2) | 25.7 ± 4.73 (16.6 - 42.9) | 24.3 ± 3.3 (16.0- 31.0) |
| MELD | 21 ± 10.4 (6 - 40) | |
| RRT before TPL (%) | 8 (16%) | |
| HRS before TPL (%) | 17 (34%) | |
| SAPS II | 30 ± 19 (0 - 91) | |
| Creatinine (μmol/l) | 121 ± 117 (40 - 814) | |
| Hematocrit (%) | 31.4 ± 7.6 (18.8 - 49.6) | |
| Platelets (103/μl) | 106 ± 65 (33 - 324) | |
| INR | 1.5 ± 0.6 (0.9 - 4.3) | |
| Bilirubin (μmol/l) | 148 ± 198 (5 - 875) | |
| Etiology of liver disease | ||
| HCV (%) | 17 (34%) | |
| HBV (%) | 3 (6%) | |
| HCC (%) | 10 (20%) | |
| Alcoholic liver cirrhosis (%) | 6 (12%) | |
| Cholangiocarcinoma (%) | 2 (4%) | |
| Others1 (%) | 12 (24%) | |
| Cadaveric Donor (%) | 44 (88%) | |
| Living Donor (%) | 6 (12%) | |
| Extended donor graft criteria (%) | 16 (32%) |
Data expressed as mean ± standard deviation (range). Abbreviations: BMI, body mass index; RRT, renal replacement therapy; TPL, transplantation; HRS, hepato-renal syndrome; SAPS, simplified acute physiology score; INR, international normalized ratio; HCV, hepatitis C virus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma. Footnote: 1) encompasses primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis liver cirrhosis, Morbus Wilson, alpha-1-antitrypsin-defiency, acute liver failure, cryptogenic liver cirrhosis, Morbus Osler, polycyclic liver disease, recurrent intrahepatic cholestasis, vanishing bile duct syndrome, haemangioendothelioma.
Postoperative ICU data (n = 50)
| ICG-PDR (%/min)1 | 19.5 ± 7.7 (4.2 - 34) |
| Bilirubin (μmol/l)2 | 133 ± 115 (17 - 568) |
| Factor V (%)3 | 57 ± 29 (4 - 114) |
| ICU stay (days) | 11.6 ± 21.9 (1 - 93) |
| Hospital stay (days) | 31.4 ± 28.0 (8 - 128) |
| Hospital Mortality (%) | 4 (8%) |
Data expressed as mean ± standard deviation (range). Abbreviations: ICG-PDR, indocyanine green plasma disappearance rate. Footnotes: 1) determined within 6 hours after ICU admission, 2) peak values within 7 days, 3) after 24 hours.
ICU and hospital stay grouped data
| ICU stay ≤4 days | ICU stay >4 days | p | Hospital stay ≤37 days | Hospital stay >37 days | p | |
|---|---|---|---|---|---|---|
| (n = 23) | (n = 27) | (n = 37) | (n = 13) | |||
| Age (yrs) | 50 (45-58) | 55 (48 - 61) | 0.11 | 50 (45 - 58) | 58 (51 - 63) | 0.033 |
| BMI (kg/m2) | 23.8 (21.1-26.6) | 26.4 (25.0 - 28.6) | 0.04 | 25.4 (22.7 - 28.5) | 25.5 (24.2 - 26.2) | 0.72 |
| MELD | 14 (86-27) | 26 (18 - 32) | 0.007 | 18 (10 - 26) | 28 (26 - 34) | <0.001 |
| ICG-PDR (%/min)1 | 23.4 (18.7-26.7) | 16.6 (8.8 - 22.8) | 0.001 | 22.8 (15.5 - 25.3) | 17.6 (10.1 - 20.8) | 0.08 |
| Bilirubin (μmol/l)2 | 94 (22-149) | 133 (61 - 214) | 0.03 | 88 (37 - 156) | 162 (116 - 214) | 0.008 |
| Factor V (%)3 | 71 (41-92) | 45 (27 - 66) | 0.03 | 53 (30 - 73) | 66 (49 - 83) | 0.35 |
Data expressed as median (25th - 75th Percentile). Footnotes: 1) determined within 6 hours after ICU admission, 2) peak values within 7 days, 3) after 24 hours.
Receiver operating characteristic analysis of MELD, ICG-PDR, bilirubin and factor V to predict the length of stay in the ICU and in the hospital as well as hospital mortality
| Cut-off value | AUC | Sensitivity (%) | Specificity (%) | p | |
|---|---|---|---|---|---|
|
| |||||
| MELD | 25 | 0.67 | 63 | 74 | 0.05 |
| ICG-PDR (%/min)1 | 20 | 0.77 | 70 | 74 | 0.001 |
| Bilirubin (μmol/l)2 | 110 | 0.68 | 67 | 65 | 0.03 |
| Factor V (%)3 | 40 | 0.75 | 67 | 74 | 0.002 |
|
| |||||
| MELD | 23 | 0.81 | 100 | 54 | 0.001 |
| ICG-PDR (%/min)1 | 20 | 0.67 | 77 | 62 | 0.08 |
| Bilirubin (μmol/l)2 | 110 | 0.75 | 92 | 62 | 0.01 |
| Factor V (%)3 | 50 | 0.52 | 77 | 40 | 0.80 |
|
| |||||
| MELD | 25 | 0.85 | 100 | 59 | 0.02 |
| ICG-PDR (%/min)1 | 20 | 0.79 | 100 | 59 | 0.05 |
| Bilirubin (μmol/l)2 | 110 | 0.68 | 100 | 54 | 0.25 |
| Factor V (%)3 | 40 | 0.72 | 100 | 44 | 0.16 |
Abbreviations: AUC, area under the curve. Footnotes: 1) determined within 6 hours after ICU admission, 2) peak values within 7 days, 3) after 24 hours.
Figure 1ROC curve analysis of parameters with different clinical outcomes. (A) Area under the curve (AUC) for MELD and ICU stay (≤4 vs. >4), (B) ICG and ICU stay, (C) MELD and hospital stay (≤37 vs. >37), (D) ICG and hospital stay, (E) MELD and hospital mortality, and (F) ICG and hospital mortality.
MELD / ICG-PDR combination for prediction of length of stay in the ICU, length of hospital stay and hospital mortality
| Positive combination | Negative combination | p | |
|---|---|---|---|
| ICU stay, median (IQR) | 9 (5-43) | 4 (3-6) | 0.004 |
| Hospital stay, median (IQR) | 42 (21-74) | 22 (15-28) | < 0.001 |
| Hospital mortality, n (%) | 4 (40%) | 0 (0% ) | 0.003 |
Positive combination: MELD >25 and ICG-PDR <20%/min. Negative combination: all other combinations. Abbreviations: IQR, interquartile range, SEM, standard error of mean.